Search

Your search keyword '"Schett, G."' showing total 1,162 results
Start Over Author "Schett, G." Search Limiters Full Text
1,162 results on '"Schett, G."'

8. Blood-based biomarkers of tissue remodeling and inflammation can discriminate between rheumatic diseases and healthy controls, and are associated with hand function

Author

Port, H, Coppers, B, Bayat, S, Godonou, ET, Valor-Méndez, L, Simon, D, Fagni, F, Corte, G, Tascilar, K, Hueber, A, Schönau, V, Sticherling, M, Leyendecker, S, Bohr, D, Schett, G, Kleyer, A, Holm Nielsen, S, Liphardt, AM, Port, H, Coppers, B, Bayat, S, Godonou, ET, Valor-Méndez, L, Simon, D, Fagni, F, Corte, G, Tascilar, K, Hueber, A, Schönau, V, Sticherling, M, Leyendecker, S, Bohr, D, Schett, G, Kleyer, A, Holm Nielsen, S, and Liphardt, AM

Published
2023

11. Langzeitdaten zu Sicherheit und Wirksamkeit der CAR-T-Zelltherapie bei refraktärem Systemischem Lupus erythematodes - Daten der ersten sieben Patienten

Author

Taubmann, J, Mueller, F, Boeltz, S, Voelkl, S, Aigner, M, Kleyer, A, Minopoulou, I, Corte, G, Gary, R, Kretschmann, S, Kharboutli, S, Mougiakakos, D, Krönke, G, Mackensen, A, Schett, G, Taubmann, J, Mueller, F, Boeltz, S, Voelkl, S, Aigner, M, Kleyer, A, Minopoulou, I, Corte, G, Gary, R, Kretschmann, S, Kharboutli, S, Mougiakakos, D, Krönke, G, Mackensen, A, and Schett, G

Published
2023

12. Objective and subjective hand function reflect grade of tenosynovitis in patients with psoriasis and psoriatic arthritis

Author

Coppers, B, Bayat, S, Godonou, ET, Valor-Mendez, L, Simon, D, Fagni, F, Corte, G, Tascilar, K, Hueber, A, Bohr, D, Schönau, V, Sticherling, M, Schett, G, Kleyer, A, Liphardt, AM, Coppers, B, Bayat, S, Godonou, ET, Valor-Mendez, L, Simon, D, Fagni, F, Corte, G, Tascilar, K, Hueber, A, Bohr, D, Schönau, V, Sticherling, M, Schett, G, Kleyer, A, and Liphardt, AM

Published
2023

14. Augmented Reality - virtuelle Patienten in der rheumatologischen Lehre

Author

Pfeil, A, Klemm, P, Hueber, A, Hoffmann, T, Oelzner, P, Weise, T, Müller-Ladner, U, Lange, U, Wolf, G, Schett, G, Simon, D, Kleyer, A, Pfeil, A, Klemm, P, Hueber, A, Hoffmann, T, Oelzner, P, Weise, T, Müller-Ladner, U, Lange, U, Wolf, G, Schett, G, Simon, D, and Kleyer, A

Published
2023

16. Disturbed spatial activation of WNT/beta-catenin signaling in Systemic Sclerosis

Author

Bergmann, C, Chenguiti Fakhouri, S, Konstantinidis, L, Zhu, H, Rigaz, A, Györfi, AH, Eckstein, M, Geppert, CI, Dees, C, Kreuter, A, Sticherling, M, Schett, G, Distler, J, Bergmann, C, Chenguiti Fakhouri, S, Konstantinidis, L, Zhu, H, Rigaz, A, Györfi, AH, Eckstein, M, Geppert, CI, Dees, C, Kreuter, A, Sticherling, M, Schett, G, and Distler, J

Published
2023

18. Novel Biomarkers Of Cartilage Metabolism Are Mechanosensitive In Response To 30 Minutes Walking In Acpa-Positive Individuals Without Signs Of Arthritis And Rheumatoid Arthritis Patients

Author

Liphardt, A.-M., primary, Godonou, E.-T., additional, Bleckwedel-Rolack, L., additional, Hühne, J., additional, Nees, V., additional, Hueber, A., additional, Rech, J., additional, Kleyer, A., additional, Karsdal, M.A., additional, Schett, G., additional, and Bay-Jensen, A.-C., additional

Published
2023
Full Text
View/download PDF

20. Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis

Author

Mease, P., Heijde, D. van der, Kirkham, B., Schett, G., Orbai, A.M., Ritchlin, C., Merola, J.F., Pricop, L., James, D.A., Zhu, X., and Ligozio, G.

Subjects
Psoriatic arthritis, Bone erosion, Radiographic damage, Joint space narrowing, Minimal disease activity
Abstract

Background Psoriatic arthritis (PsA) patient data from two phase 3 secukinumab trials (FUTURE 1, 5) were analysed to quantify the prevalence and extent of pre-existing radiographic damage (RD) at baseline; investigate the association of RD with swollen/tender joint counts (SJC/TJC) at baseline; and investigate the extent to which RD at baseline correlated with response to secukinumab. Methods Pooled data (N = 1554) provided baseline radiographic bone erosion and joint space narrowing (JSN) scores at pre-specified locations per the van der Heijde-modified total Sharp score (vdH-mTSS) for PsA and swollen and tender joint scores in the same joints at multiple visits. Overall patient RD and individual joints RD bone erosion and JSN scores were assessed. The association between joint activity (tenderness, swelling) and vdH-mTSS was assessed at the overall patient-level and individual joint tender, swollen scores (yes/no) and RD joint JSN and bone erosion scores at the individual joint-level. Treatment response was assessed using SJC/TJC at weeks 16 and 52 and the proportion of patients achieving minimal disease activity (MDA) over all assessments within 1 year from FUTURE 5 alone. Results A substantial prevalence of pre-existing RD with higher prevalence of erosion than JSN was observed (86% and 60% of patients had positive erosion and JSN scores, respectively); higher RD prevalence was associated with longer time since PsA diagnosis. Joint activity was weakly associated with RD at baseline at the patient-level (Pearson’s coefficients: range 0.12–0.18), but strongly associated at the individual joint-level, with a higher probability of tender/swollen joints to associate with higher JSN/erosion scores: all 42 analysed joints showed statistical significance at the 0.05 level (unadjusted) for the relationship between joint tenderness (yes/no) and its JSN score, all but one for tenderness and bone erosion scores, and all but 2 for swollen and JSN scores and for swollen and bone erosion score. Secukinumab (150/300 mg), reduced TJC and SJC across all values of baseline erosion and JSN scores at weeks 16 and 52. Patients with higher levels of RD were less likely to achieve zero tender/zero swollen joint status and had lower chance of achieving MDA. Conclusions PsA patients showed substantial prevalence of RD at baseline that correlated with time since diagnosis, but patient’s individual joint activity was strongly associated with pre-existing RD at those joints. Patients with the highest RD at baseline had a reduced likelihood of achieving zero joint count status.

Published
2022

21. ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis

Author

Bütikofer L, Varisco PA, Distler O, Kowal-Bielecka O, Allanore Y, Riemekasten G, Villiger PM, Adler S, Avouac J, Walker UA, Guiducci S, Airò P, Hachulla E, Valentini G, Carreira PE, Cozzi F, Gurman AB, Braun-Moscovici Y, Damjanov N, Ananieva LP, Scorza R, Jimenez S, Busquets J, Li M, Müller-Ladner U, Maurer B, Tyndall A, Lapadula G, Iannone F, Becvar R, Sierakowsky S, Bielecka OK, Cutolo M, Sulli A, Cuomo G, Vettori S, Rednic S, Nicoara I, Vlachoyiannopoulos P, Montecucco C, Caporali R, Novak S, Czirják L, Varju C, Chizzolini C, Kucharz EJ, Kotulska A, Kopec-Medrek M, Widuchowska M, Rozman B, Mallia C, Coleiro B, Gabrielli A, Farge D, Hij A, Hesselstrand R, Scheja A, Wollheim F, Martinovic D, Govoni M, Monaco AL, Hunzelmann N, Pellerito R, Bambara LM, Caramaschi P, Black C, Denton C, Henes J, Santamaria VO, Heitmann S, Krasowska D, Seidel M, Oleszowsky M, Burkhardt H, Himsel A, Salvador MJ, Stamenkovic B, Stankovic A, Tikly M, Starovoytova MN, Engelhart M, Strauss G, Nielsen H, Damgaard K, Szücs G, Mendoza AZ, de la Puente Buijdos C, Sifuentes Giraldo WA, Midtvedt Ø, Garen T, Launay D, Valesini G, Riccieri V, Ionescu RM, Opris D, Groseanu L, Wigley FM, Mihai CM, Cornateanu RS, Ionitescu R, Gherghe AM, Gorga M, Dobrota R, Bojinca M, Schett G, Distler JHW, Meroni P, Zeni S, Mouthon L, De Keyser F, Smith V, Cantatore FP, Corrado A, Ullman S, Iversen L, Pozzi MR, Eyerich K, Hein R, Knott E, Szechinski J, Wiland P, Szmyrka-Kaczmarek M, Sokolik R, Morgiel E, Krummel-Lorenz B, Saar P, Aringer M, Günther C, Anic B, Baresic M, Mayer M, Radominski SC, de Souza Müller C, Azevedo VF, Agachi S, Groppa L, Chiaburu L, Russu E, Zenone T, Stebbings S, Highton J, Stamp L, Chapman P, Baron M, O'Donnell J, Solanki K, Doube A, Veale D, O'Rourke M, Loyo E, Rosato E, Pisarri S, Tanaseanu CM, Popescu M, Dumitrascu A, Tiglea I, Chirieac R, Ancuta C, Furst DE, Kafaja S, de la Peña Lefebvre PG, Rubio SR, Exposito MV, Sibilia J, Chatelus E, Gottenberg JE, Chifflot H, Litinsky I, Venalis A, Butrimiene I, Venalis P, Rugiene R, Karpec D, Kerzberg E, Montoya F, Cosentino V, Castellvi I., Publica, Bütikofer, L, Varisco, Pa, Distler, O, Kowal-Bielecka, O, Allanore, Y, Riemekasten, G, Villiger, Pm, Adler, S, Avouac, J, Walker, Ua, Guiducci, S, Airò, P, Hachulla, E, Valentini, G, Carreira, Pe, Cozzi, F, Gurman, Ab, Braun-Moscovici, Y, Damjanov, N, Ananieva, Lp, Scorza, R, Jimenez, S, Busquets, J, Li, M, Müller-Ladner, U, Maurer, B, Tyndall, A, Lapadula, G, Iannone, F, Becvar, R, Sierakowsky, S, Bielecka, Ok, Cutolo, M, Sulli, A, Cuomo, G, Vettori, S, Rednic, S, Nicoara, I, Vlachoyiannopoulos, P, Montecucco, C, Caporali, R, Novak, S, Czirják, L, Varju, C, Chizzolini, C, Kucharz, Ej, Kotulska, A, Kopec-Medrek, M, Widuchowska, M, Rozman, B, Mallia, C, Coleiro, B, Gabrielli, A, Farge, D, Hij, A, Hesselstrand, R, Scheja, A, Wollheim, F, Martinovic, D, Govoni, M, Monaco, Al, Hunzelmann, N, Pellerito, R, Bambara, Lm, Caramaschi, P, Black, C, Denton, C, Henes, J, Santamaria, Vo, Heitmann, S, Krasowska, D, Seidel, M, Oleszowsky, M, Burkhardt, H, Himsel, A, Salvador, Mj, Stamenkovic, B, Stankovic, A, Tikly, M, Starovoytova, Mn, Engelhart, M, Strauss, G, Nielsen, H, Damgaard, K, Szücs, G, Mendoza, Az, de la Puente Buijdos, C, Sifuentes Giraldo, Wa, Midtvedt, Ø, Garen, T, Launay, D, Valesini, G, Riccieri, V, Ionescu, Rm, Opris, D, Groseanu, L, Wigley, Fm, Mihai, Cm, Cornateanu, R, Ionitescu, R, Gherghe, Am, Gorga, M, Dobrota, R, Bojinca, M, Schett, G, Distler, Jhw, Meroni, P, Zeni, S, Mouthon, L, De Keyser, F, Smith, V, Cantatore, Fp, Corrado, A, Ullman, S, Iversen, L, Pozzi, Mr, Eyerich, K, Hein, R, Knott, E, Szechinski, J, Wiland, P, Szmyrka-Kaczmarek, M, Sokolik, R, Morgiel, E, Krummel-Lorenz, B, Saar, P, Aringer, M, Günther, C, Anic, B, Baresic, M, Mayer, M, Radominski, Sc, de Souza Müller, C, Azevedo, Vf, Agachi, S, Groppa, L, Chiaburu, L, Russu, E, Zenone, T, Stebbings, S, Highton, J, Stamp, L, Chapman, P, Baron, M, O'Donnell, J, Solanki, K, Doube, A, Veale, D, O'Rourke, M, Loyo, E, Rosato, E, Pisarri, S, Tanaseanu, Cm, Popescu, M, Dumitrascu, A, Tiglea, I, Chirieac, R, Ancuta, C, Furst, De, Kafaja, S, de la Peña Lefebvre, Pg, Rubio, Sr, Exposito, Mv, Sibilia, J, Chatelus, E, Gottenberg, Je, Chifflot, H, Litinsky, I, Venalis, A, Butrimiene, I, Venalis, P, Rugiene, R, Karpec, D, Kerzberg, E, Montoya, F, Cosentino, V, and Castellvi, I.

Subjects
INVOLVEMENT, Male, Hypertension, Renal, ACE inhibitors, lcsh:Diseases of the musculoskeletal system, Scleroderma Renal Crisis, MULTICENTER, Angiotensin-Converting Enzyme Inhibitors, Scleroderma, Scleroderma renal crisis, 0302 clinical medicine, Risk Factors, Medicine and Health Sciences, Medicine, 030212 general & internal medicine, Prospective Studies, 610 Medicine & health, Renal, Antihypertensive drugs, Outcome, antihypertensive drugs, arterial hypertension, outcome, scleroderma renal crisis, Incidence (epidemiology), Incidence, Hazard ratio, Acute Kidney Injury, Middle Aged, Europe, Treatment Outcome, Population Surveillance, Cohort, Hypertension, Female, 360 Social problems & social services, Proto-oncogene tyrosine-protein kinase Src, Research Article, Arterial hypertension, medicine.medical_specialty, 03 medical and health sciences, ENDOTHELIN-1, Internal medicine, Humans, Risk factor, Aged, 030203 arthritis & rheumatology, Scleroderma, Systemic, business.industry, SYSTEMIC-SCLEROSIS, Systemic, medicine.disease, Concomitant, lcsh:RC925-935, business
Abstract

Objectives To investigate the effect of ACE inhibitors (ACEi) on the incidence of scleroderma renal crisis (SRC) when given prior to SRC in the prospectively collected cohort from the European Scleroderma Trial and Research Group (EUSTAR). Methods SSc patients without prior SRC and at least one follow-up visit were included and analyzed regarding SRC, arterial hypertension, and medication focusing on antihypertensive medication and glucocorticoids (GC). Results Out of 14,524 patients in the database, we identified 7648 patients with at least one follow-up. In 27,450 person-years (py), 102 patients developed SRC representing an incidence of 3.72 (3.06–4.51) per 1000 py. In a multivariable time-to-event analysis adjusted for age, sex, disease severity, and onset, 88 of 6521 patients developed SRC. The use of ACEi displayed an increased risk for the development of SRC with a hazard ratio (HR) of 2.55 (95% confidence interval (CI) 1.65–3.95). Adjusting for arterial hypertension resulted in a HR of 2.04 (95%CI 1.29–3.24). There was no evidence for an interaction of ACEi and arterial hypertension (HR 0.83, 95%CI 0.32–2.13, p = 0.69). Calcium channel blockers (CCB), angiotensin receptor blockers (ARB), endothelin receptor antagonists, and GC—mostly in daily dosages below 15 mg of prednisolone—did not influence the hazard for SRC. Conclusions ACEi in SSc patients with concomitant arterial hypertension display an independent risk factor for the development of SRC but are still first choice in SRC treatment. ARBs might be a safe alternative, yet the overall safety of alternative antihypertensive drugs in SSc patients needs to be further studied.

Published
2020
Full Text
View/download PDF

23. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis

Author

Nagy, G., Roodenrijs, N.M., Welsing, P.M., Kedves, M., Hamar, A., van der Goes, M.C., Kent, A., Bakkers, M., Pchelnikova, P., Blaas, E., Senolt, L., Szekanecz, Z., Choy, E., Dougados, M., Jacobs, J.W., Geenen, R., Bijlsma, J.W., Zink, A., Aletaha, D., Schoneveld, L., van Riel, P., Dumas, S., Prior, Y., Nikiphorou, E., Ferraccioli, G., Schett, G., Hyrich, K.L., Mueller-Ladner, U., Buch, M.H., McInnes, I.B., van der Heijde, D., van Laar, J.M., Nagy, G., Roodenrijs, N.M., Welsing, P.M., Kedves, M., Hamar, A., van der Goes, M.C., Kent, A., Bakkers, M., Pchelnikova, P., Blaas, E., Senolt, L., Szekanecz, Z., Choy, E., Dougados, M., Jacobs, J.W., Geenen, R., Bijlsma, J.W., Zink, A., Aletaha, D., Schoneveld, L., van Riel, P., Dumas, S., Prior, Y., Nikiphorou, E., Ferraccioli, G., Schett, G., Hyrich, K.L., Mueller-Ladner, U., Buch, M.H., McInnes, I.B., van der Heijde, D., and van Laar, J.M.

Abstract

Objective: To develop evidence- based European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) for the management of difficult- to- treat rheumatoid arthritis (D2T RA). Methods: An EULAR Task Force was established comprising 34 individuals: 26 rheumatologists, patient partners and rheumatology experienced health professionals. Two systematic literature reviews addressed clinical questions around diagnostic challenges, and pharmacological and non- pharmacological therapeutic strategies in D2T RA. PtCs were formulated based on the identified evidence and expert opinion. Strength of recommendations (SoR, scale A–D: A typically consistent level 1 studies and D level 5 evidence or inconsistent studies) and level of agreement (LoA, scale 0–10: 0 completely disagree and 10 completely agree) of the PtCs were determined by the Task Force members. Results: Two overarching principles and 11 PtCs were defined concerning diagnostic confirmation of RA, evaluation of inflammatory disease activity, pharmacological and non- pharmacological interventions, treatment adherence, functional disability, pain, fatigue, goal setting and self- efficacy and the impact of comorbidities. The SoR varied from level C to level D. The mean LoA with the overarching principles and PtCs was generally high (8.4–9.6). Conclusions: These PtCs for D2T RA can serve as a clinical roadmap to support healthcare professionals and patients to deliver holistic management and more personalised pharmacological and non- pharmacological therapeutic strategies. High- quality evidence was scarce. A research agenda was created to guide future research

Published
2022

24. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis

Author

Leerstoel Geenen, Clinical Psychology (overkoepelend voor heel KP), Nagy, G., Roodenrijs, N.M., Welsing, P.M., Kedves, M., Hamar, A., van der Goes, M.C., Kent, A., Bakkers, M., Pchelnikova, P., Blaas, E., Senolt, L., Szekanecz, Z., Choy, E., Dougados, M., Jacobs, J.W., Geenen, R., Bijlsma, J.W., Zink, A., Aletaha, D., Schoneveld, L., van Riel, P., Dumas, S., Prior, Y., Nikiphorou, E., Ferraccioli, G., Schett, G., Hyrich, K.L., Mueller-Ladner, U., Buch, M.H., McInnes, I.B., van der Heijde, D., van Laar, J.M., Leerstoel Geenen, Clinical Psychology (overkoepelend voor heel KP), Nagy, G., Roodenrijs, N.M., Welsing, P.M., Kedves, M., Hamar, A., van der Goes, M.C., Kent, A., Bakkers, M., Pchelnikova, P., Blaas, E., Senolt, L., Szekanecz, Z., Choy, E., Dougados, M., Jacobs, J.W., Geenen, R., Bijlsma, J.W., Zink, A., Aletaha, D., Schoneveld, L., van Riel, P., Dumas, S., Prior, Y., Nikiphorou, E., Ferraccioli, G., Schett, G., Hyrich, K.L., Mueller-Ladner, U., Buch, M.H., McInnes, I.B., van der Heijde, D., and van Laar, J.M.

Published
2022

25. Langfristige humorale Immunantwort auf die SARS-CoV-2-Impfung bei Patienten mit immunvermittelten entzündlichen Erkrankungen

Author

Tascilar, K, Simon, D, Kleyer, A, Fagni, F, Krönke, G, Meder, C, Dietrich, P, Orlemann, T, Kliem, T, Mößner, J, Liphardt, AM, Schönau, V, Bohr, D, Schuster, L, Hartmann, F, Taubmann, J, Minopoulou, I, Leppkes, M, Ramming, A, Pachowsky, M, Schuch, F, Ronneberger, M, Kleinert, S, Hueber, A, Manger, K, Manger, B, Atreya, R, Berking, C, Sticherling, M, Neurath, MF, Schett, G, Tascilar, K, Simon, D, Kleyer, A, Fagni, F, Krönke, G, Meder, C, Dietrich, P, Orlemann, T, Kliem, T, Mößner, J, Liphardt, AM, Schönau, V, Bohr, D, Schuster, L, Hartmann, F, Taubmann, J, Minopoulou, I, Leppkes, M, Ramming, A, Pachowsky, M, Schuch, F, Ronneberger, M, Kleinert, S, Hueber, A, Manger, K, Manger, B, Atreya, R, Berking, C, Sticherling, M, Neurath, MF, and Schett, G

Published
2022

26. Triage in der Rheumatologie - eine Bestandsaufnahme

Author

Knitza, J, Fuchs, F, Morf, H, Mohn, J, Mühlensiepen, F, Ignatyev, Y, Bohr, D, Araujo, E, Bergmann, C, Simon, D, Kleyer, A, Vorbrüggen, W, Ramming, A, Distler, J, Bartz-Bazzanella, P, Schett, G, Welcker, M, Hueber, A, Knitza, J, Fuchs, F, Morf, H, Mohn, J, Mühlensiepen, F, Ignatyev, Y, Bohr, D, Araujo, E, Bergmann, C, Simon, D, Kleyer, A, Vorbrüggen, W, Ramming, A, Distler, J, Bartz-Bazzanella, P, Schett, G, Welcker, M, and Hueber, A

Published
2022

27. Nicht-invasives metabolisches in-vivo Profiling von Entzündung in Gelenken und Sehnenansätzen mit Hilfe von optoakustischer Bildgebung

Author

Tascilar, K, Fagni, F, Kleyer, A, Bayat, S, Heidemann, R, Steiger, F, Krönke, G, Bohr, D, Ramming, A, Hartmann, F, Minopoulou, I, Al Ahmad, N, Klett, D, Federle, A, Regensburger, A, Wagner, AL, Knieling, F, Neurath, MF, Schett, G, Waldner, M, Simon, D, Tascilar, K, Fagni, F, Kleyer, A, Bayat, S, Heidemann, R, Steiger, F, Krönke, G, Bohr, D, Ramming, A, Hartmann, F, Minopoulou, I, Al Ahmad, N, Klett, D, Federle, A, Regensburger, A, Wagner, AL, Knieling, F, Neurath, MF, Schett, G, Waldner, M, and Simon, D

Published
2022

28. Eigenständige Entnahme von Kapillarblut durch Patient:innen mit systemischen rheumatischen Erkrankungen - eine qualitative Interviewstudie zur Exploration der Patient:innen- und Versorger:innen-Perspektive

Author

Mühlensiepen, F, May, S, Zarbl, J, Vogt, E, Hadaschik, K, Heinze, M, Böltz, S, Labinsky, H, Bendzuck, G, Korinth, M, Elling-Audersch, C, Vuillerme, N, Schett, G, Krönke, G, Knitza, J, Mühlensiepen, F, May, S, Zarbl, J, Vogt, E, Hadaschik, K, Heinze, M, Böltz, S, Labinsky, H, Bendzuck, G, Korinth, M, Elling-Audersch, C, Vuillerme, N, Schett, G, Krönke, G, and Knitza, J

Published
2022

33. Die 'ARIAA-Studie' - Abatacept verzögert den Übergang in eine RA bei at-risk-Patienten - klinische Ergebnisse zu Monat 18 der internationalen, randomisiert, placebo kontrollierten Studie

Author

Rech, J, Kleyer, A, Ostergaard, M, Feuchtenberger, M, Hagen, M, Valor Mendez, L, Koray, T, Kroenke, G, Schönau, V, Kleinert, S, Baraliakos, X, Braun, J, Fleck, M, Rubbert-Roth, A, Behrens, F, Zaenker, M, Kofler, DM, Simon, D, Glaser, C, Hueber, A, Voll, R, Feist, E, Burmester, GR, Karberg, K, Strunk, J, Cañete, JdD, Senolt, L, Naredo, E, Schett, G, Rech, J, Kleyer, A, Ostergaard, M, Feuchtenberger, M, Hagen, M, Valor Mendez, L, Koray, T, Kroenke, G, Schönau, V, Kleinert, S, Baraliakos, X, Braun, J, Fleck, M, Rubbert-Roth, A, Behrens, F, Zaenker, M, Kofler, DM, Simon, D, Glaser, C, Hueber, A, Voll, R, Feist, E, Burmester, GR, Karberg, K, Strunk, J, Cañete, JdD, Senolt, L, Naredo, E, and Schett, G

Published
2022

35. Eine randomisierte, kontrollierte, Investigator-verblindete, multizentrische, interventionelle Pilotstudie zur Untersuchung der Auswirkung einer Virtual Reality unterstützten Schulung von medizinischen Fachangestellten über rheumatoide Arthritis: Die VENTURE-Studie

Author

Klemm, P, Hain, F, Hain, AC, Mattukat, K, Asendorf, T, Lange, U, Müller-Ladner, U, Schett, G, Kleyer, A, Hueber, AJ, Pfeil, A, Simon, D, Klemm, P, Hain, F, Hain, AC, Mattukat, K, Asendorf, T, Lange, U, Müller-Ladner, U, Schett, G, Kleyer, A, Hueber, AJ, Pfeil, A, and Simon, D

Published
2022

36. Targeting of fibroblast activation protein in rheumatoid arthritis patients: imaging and ex vivo photodynamic therapy

Author

Dorst, D.N., Rijpkema, M.J.P., Buitinga, M., Walgreen, B., Helsen, M.M.A., Brennan, E., Klein, C., Laverman, P., Ramming, A., Schmidkonz, C., Kuwert, T., Schett, G., Kraan, P.M. van der, Gotthardt, M., Koenders, M.I., Dorst, D.N., Rijpkema, M.J.P., Buitinga, M., Walgreen, B., Helsen, M.M.A., Brennan, E., Klein, C., Laverman, P., Ramming, A., Schmidkonz, C., Kuwert, T., Schett, G., Kraan, P.M. van der, Gotthardt, M., and Koenders, M.I.

Abstract

Contains fulltext : 282880.pdf (Publisher’s version ) (Open Access), OBJECTIVE: Activated synovial fibroblasts are key effector cells in RA. Selectively depleting these based upon their expression of fibroblast activation protein (FAP) is an attractive therapeutic approach. Here we introduce FAP imaging of inflamed joints using 68Ga-FAPI-04 in a RA patient, and aim to assess feasibility of anti-FAP targeted photodynamic therapy (FAP-tPDT) ex vivo using 28H1-IRDye700DX on RA synovial explants. METHODS: Remnant synovial tissue from RA patients was processed into 6 mm biopsies and, from several patients, into primary fibroblast cell cultures. Both were treated using FAP-tPDT. Cell viability was measured in fibroblast cultures and biopsies were evaluated for histological markers of cell damage. Selectivity of the effect of FAP-tPDT was assessed using flow cytometry on primary fibroblasts and co-cultured macrophages. Additionally, one RA patient intravenously received 68Ga-FAPI-04 and was scanned using PET/CT imaging. RESULTS: In the RA patient, FAPI-04 PET imaging showed high accumulation of the tracer in arthritic joints with very low background signal. In vitro, FAP-tPDT induced cell death in primary RA synovial fibroblasts in a light dose-dependent manner. An upregulation of cell damage markers was observed in the synovial biopsies after FAP-tPDT. No significant effects of FAP-tPDT were noted on macrophages after FAP-tPDT of neighbouring fibroblasts. CONCLUSION: In this study the feasibility of selective FAP-tPDT in synovium of rheumatoid arthritis patients ex vivo is demonstrated. Furthermore, this study provides the first indication that FAP-targeted PET/CT can be used to image arthritic joints, an important step towards application of FAP-tPDT as a targeted locoregional therapy for RA.

Published
2022

37. ABATACEPT DELAYS THE DEVELOPMENT OF RA-CLINICAL RESULTS AFTER 18 MONTHS FROM THE RANDOMIZED, PLACEBO-CONTROLLED ARIAA STUDY IN RA-AT RISK PATIENTS

Author

Rech, J., Kleyer, A., Ostergaard, M., Hagen, M., Valor, L., Tascilar, K., Kronke, G., Schonau, V., Kleinert, S., Baraliakos, X., Braun, J., Fleck, M., Rubbert-Roth, A., Behrens, F., Feuchtenberger, M., Zaenker, M., Kofler, D. M., Voll, R., Glaser, C., Hueber, A., Feist, E., Burmester, G. R., Karberg, K., Strunk, J., Canete, J. D. D., Senolt, L., Naredo, E., Schett, G., Rech, J., Kleyer, A., Ostergaard, M., Hagen, M., Valor, L., Tascilar, K., Kronke, G., Schonau, V., Kleinert, S., Baraliakos, X., Braun, J., Fleck, M., Rubbert-Roth, A., Behrens, F., Feuchtenberger, M., Zaenker, M., Kofler, D. M., Voll, R., Glaser, C., Hueber, A., Feist, E., Burmester, G. R., Karberg, K., Strunk, J., Canete, J. D. D., Senolt, L., Naredo, E., and Schett, G.

Published
2022

38. Rheumatoid arthritis, as a clinical disease, but not rheumatoid arthritis-associated autoimmunity, is linked to cardiovascular events

Author

Gouze, H., Aegerter, P., Said-Nahal, R., Zins, M., Goldberg, M., Morelle, G., Schett, G., Breban, M., D'Agostino, Maria Antonietta, D'Agostino M. A. (ORCID:0000-0002-5347-0060), Gouze, H., Aegerter, P., Said-Nahal, R., Zins, M., Goldberg, M., Morelle, G., Schett, G., Breban, M., D'Agostino, Maria Antonietta, and D'Agostino M. A. (ORCID:0000-0002-5347-0060)

Abstract

Background: Rheumatoid arthritis (RA) is characterized by increased cardiovascular (CV) mortality. CV events are particularly high in patients with RA-specific autoimmunity, including rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), raising the question whether RA-specific autoimmunity itself is associated with CV events. Methods: New CV events (myocardial infarction, stroke or death by CV cause) were recorded in 20,625 subjects of the Electricité de France – Gaz de France (GAZEL) cohort. Self-reported RA cases in the GAZEL cohort were validated by phone interview on the basis of a specific questionnaire. In 1618 subjects, in whom plasma was available, RF and ACPA were measured. A piecewise exponential Poisson regression was used to analyze the association of CV events with presence of RA as well as RA-specific autoimmunity (without RA). Results: CV events in GAZEL were associated with age, male sex, smoking, hypertension, hyperlipidemia, and diabetes mellitus (HR from 1.06 to 1.87, p < 0.05). Forty-two confirmed RA cases were identified. Confirmed RA was significantly associated with CV risk increase (HR of 3.03; 95% CI: 1.13–8.11, p = 0.03) independently of conventional CV risk factors. One hundred seventy-eight subjects showed RF or ACPA positivity without presence of RA. CV events were not associated with ACPA positivity (HR: 1.52, 95% CI: 0.47–4.84, p = 0.48) or RF positivity (HR: 1.15, 95% CI: 0.55–2.40, p = 0.70) in the absence of RA. Conclusions: RA, as a clinical chronic inflammatory disease, but not mere positivity for RF or ACPA in the absence of clinical disease is associated with increased CV risk.

Published
2022

40. Calibration by differentiation - Self-supervised calibration for X-ray microscopy using a differentiable cone-beam reconstruction operator

Author

Thies, M., Wagner, F., Huang, Y., Gu, M., Kling, L., Pechmann, Sabrina, Aust, O., Grüneboom, A., Schett, G., Christiansen, Silke, Maier, A., and Publica

Subjects
reconstruction, known operator learning, inverse problems, deep learning, computed tomography, X-ray microscopy
Abstract

High-resolution X-ray microscopy (XRM) is gaining interest for biological investigations of extremely small-scale structures. XRM imaging of bones in living mice could provide new insights into the emergence and treatment of osteoporosis by observing osteocyte lacunae, which are holes in the bone of few micrometres in size. Imaging living animals at that resolution, however, is extremely challenging and requires very sophisticated data processing converting the raw XRM detector output into reconstructed images. This paper presents an open-source, differentiable reconstruction pipeline for XRM data which analytically computes the final image from the raw measurements. In contrast to most proprietary reconstruction software, it offers the user full control over each processing step and, additionally, makes the entire pipeline deep learning compatible by ensuring differentiability. This allows fitting trainable modules both before and after the actual reconstruction step in a purely data-driven way using the gradient-based optimizers of common deep learning frameworks. The value of such differentiability is demonstrated by calibrating the parameters of a simple cupping correction module operating on the raw projection images using only a self-supervisory quality metric based on the reconstructed volume and no further calibration measurements. The retrospective calibration directly improves image quality as it avoids cupping artefacts and decreases the difference in grey values between outer and inner bone by 68–94%. Furthermore, it makes the reconstruction process entirely independent of the XRM manufacturer and paves the way to explore modern deep learning reconstruction methods for arbitrary XRM and, potentially, other flat-panel computed tomography systems. This exemplifies how differentiable reconstruction can be leveraged in the context of XRM and, hence, is an important step towards the goal of reducing the resolution limit of in vivo bone imaging to the single micrometre domain.

Published
2022

42. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout

Author

Bursill, D, Taylor, W, Terkeltaub, R, Abhishek, A, A. K., S, Vargas-Santos, A, Gaffo, A, Rosenthal, A, Tausche, A, Reginato, A, Manger, B, Scire, C, Pineda, C, Van Durme, C, Lin, C, Yin, C, Albert, D, Biernat-Kaluza, E, Roddy, E, Pascual, E, Becce, F, Perez-Ruiz, F, Sivera, F, Liote, F, Schett, G, Nuki, G, Filippou, G, Mccarthy, G, Da Rocha Castelar Pinheiro, G, H. -K., E, Tupinamba, H, Yamanaka, H, Choi, H, Mackay, J, Odell, J, Vazquez Mellado, J, Singh, J, Fitzgerald, J, Jacobsson, L, Joosten, L, Harrold, L, Stamp, L, Andres, M, Gutierrez, M, Kuwabara, M, Dehlin, M, Janssen, M, Doherty, M, Hershfield, M, Pillinger, M, Edwards, N, Schlesinger, N, Kumar, N, Slot, O, Ottaviani, S, Richette, P, Macmullan, P, Chapman, P, Lipsky, P, Robinson, P, Khanna, P, Gancheva, R, Grainger, R, Johnson, R, Te Kampe, R, Keenan, R, Tedeschi, S, Kim, S, Choi, S, Fields, T, Bardin, T, Uhlig, T, Jansen, T, Merriman, T, Pascart, T, Neogi, T, Kluck, V, Louthrenoo, W, Dalbeth, N, Bursill D., Taylor W. J., Terkeltaub R., Abhishek A., So A. K., Vargas-Santos A. B., Gaffo A. L., Rosenthal A., Tausche A. -K., Reginato A., Manger B., Scire CA., Pineda C., Van Durme C., Lin C. -T., Yin C., Albert D. A., Biernat-Kaluza E., Roddy E., Pascual E., Becce F., Perez-Ruiz F., Sivera F., Liote F., Schett G., Nuki G., Filippou G., Mccarthy G., Da Rocha Castelar Pinheiro G., Ea H. -K., Tupinamba H. D. A., Yamanaka H., Choi H. K., Mackay J., Odell J. R., Vazquez Mellado J., Singh J. A., Fitzgerald J. D., Jacobsson L. T. H., Joosten L., Harrold L. R., Stamp L., Andres M., Gutierrez M., Kuwabara M., Dehlin M., Janssen M., Doherty M., Hershfield M. S., Pillinger M., Edwards N. L., Schlesinger N., Kumar N., Slot O., Ottaviani S., Richette P., Macmullan P. A., Chapman P. T., Lipsky P. E., Robinson P., Khanna P. P., Gancheva R. N., Grainger R., Johnson R. J., Te Kampe R., Keenan R. T., Tedeschi S. K., Kim S., Choi S. J., Fields T. R., Bardin T., Uhlig T., Jansen T., Merriman T., Pascart T., Neogi T., Kluck V., Louthrenoo W., Dalbeth N., Bursill, D, Taylor, W, Terkeltaub, R, Abhishek, A, A. K., S, Vargas-Santos, A, Gaffo, A, Rosenthal, A, Tausche, A, Reginato, A, Manger, B, Scire, C, Pineda, C, Van Durme, C, Lin, C, Yin, C, Albert, D, Biernat-Kaluza, E, Roddy, E, Pascual, E, Becce, F, Perez-Ruiz, F, Sivera, F, Liote, F, Schett, G, Nuki, G, Filippou, G, Mccarthy, G, Da Rocha Castelar Pinheiro, G, H. -K., E, Tupinamba, H, Yamanaka, H, Choi, H, Mackay, J, Odell, J, Vazquez Mellado, J, Singh, J, Fitzgerald, J, Jacobsson, L, Joosten, L, Harrold, L, Stamp, L, Andres, M, Gutierrez, M, Kuwabara, M, Dehlin, M, Janssen, M, Doherty, M, Hershfield, M, Pillinger, M, Edwards, N, Schlesinger, N, Kumar, N, Slot, O, Ottaviani, S, Richette, P, Macmullan, P, Chapman, P, Lipsky, P, Robinson, P, Khanna, P, Gancheva, R, Grainger, R, Johnson, R, Te Kampe, R, Keenan, R, Tedeschi, S, Kim, S, Choi, S, Fields, T, Bardin, T, Uhlig, T, Jansen, T, Merriman, T, Pascart, T, Neogi, T, Kluck, V, Louthrenoo, W, Dalbeth, N, Bursill D., Taylor W. J., Terkeltaub R., Abhishek A., So A. K., Vargas-Santos A. B., Gaffo A. L., Rosenthal A., Tausche A. -K., Reginato A., Manger B., Scire CA., Pineda C., Van Durme C., Lin C. -T., Yin C., Albert D. A., Biernat-Kaluza E., Roddy E., Pascual E., Becce F., Perez-Ruiz F., Sivera F., Liote F., Schett G., Nuki G., Filippou G., Mccarthy G., Da Rocha Castelar Pinheiro G., Ea H. -K., Tupinamba H. D. A., Yamanaka H., Choi H. K., Mackay J., Odell J. R., Vazquez Mellado J., Singh J. A., Fitzgerald J. D., Jacobsson L. T. H., Joosten L., Harrold L. R., Stamp L., Andres M., Gutierrez M., Kuwabara M., Dehlin M., Janssen M., Doherty M., Hershfield M. S., Pillinger M., Edwards N. L., Schlesinger N., Kumar N., Slot O., Ottaviani S., Richette P., Macmullan P. A., Chapman P. T., Lipsky P. E., Robinson P., Khanna P. P., Gancheva R. N., Grainger R., Johnson R. J., Te Kampe R., Keenan R. T., Tedeschi S. K., Kim S., Choi S. J., Fields T. R., Bardin T., Uhlig T., Jansen T., Merriman T., Pascart T., Neogi T., Kluck V., Louthrenoo W., and Dalbeth N.

Abstract

Objective There is a lack of standardisation in the terminology used to describe gout. The aim of this project was to develop a consensus statement describing the recommended nomenclature for disease states of gout. Methods A content analysis of gout-related articles from rheumatology and general internal medicine journals published over a 5-year period identified potential disease states and the labels commonly assigned to them. Based on these findings, experts in gout were invited to participate in a Delphi exercise and face-to-face consensus meeting to reach agreement on disease state labels and definitions. Results The content analysis identified 13 unique disease states and a total of 63 unique labels. The Delphi exercise (n=76 respondents) and face-to-face meeting (n=35 attendees) established consensus agreement for eight disease state labels and definitions. The agreed labels were as follows: asymptomatic hyperuricaemia', asymptomatic monosodium urate crystal deposition', asymptomatic hyperuricaemia with monosodium urate crystal deposition', gout', tophaceous gout', erosive gout', first gout flare' and recurrent gout flares'. There was consensus agreement that the label gout' should be restricted to current or prior clinically evident disease caused by monosodium urate crystal deposition (gout flare, chronic gouty arthritis or subcutaneous tophus). Conclusion Consensus agreement has been established for the labels and definitions of eight gout disease states, including gout' itself. The Gout, Hyperuricaemia and Crystal-Associated Disease Network recommends the use of these labels when describing disease states of gout in research and clinical practice.

Published
2019

43. Neuronale Netze ermöglichen die Klassifizierung rheumatischer Erkrankung anhand der Knochenform

Author

Kleyer, A, Folle, L, Simon, D, Liphardt, AM, Krönke, G, Schett, G, and Maier, A

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Eine zuverlässige Klassifizierung und Diagnose einer entzündlichen Arthritis (RMD) wie rheumatoide Arthritis (RA) oder Psoriasis-Arthritis (PsA) ist entscheidend für eine erfolgreiche Behandlung. Erosionen, Osteophyten oder Enthesiophyten an Gelenkknochen können Folge[zum vollständigen Text gelangen Sie über die oben angegebene URL], Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2021
Full Text
View/download PDF

46. Accuracy and performance of a handheld ultrasound device to assess articular and periarticular pathologies in patients with inflammatory arthritis

Author

Corte, G, Bayat, S, Tascilar, K, Valor-Méndez, L, Schuster, L, Knitza, J, Schett, G, Kleyer, A, and Simon, D

Subjects
ddc: 610, education, 610 Medical sciences, Medicine
Abstract

Introduction: Handheld ultrasound (HHUS) devices have increasingly found their way into clinical practice due to several advantages (e.g. portability, significantly lower purchase cost). However, there is no evidence to date on the accuracy and performance of HHUS in patients with inflammatory arthritis[for full text, please go to the a.m. URL], Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2021
Full Text
View/download PDF

47. Dosierung von bDMARDs in axSpA und PsA in der rheumatologischen Routineversorgung

Author

Regierer, A, Weiß, A, Poddubnyy, D, Kellner, H, Behrens, F, Schett, G, Braun, J, Sieper, J, and Strangfeld, A

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Mit der Einführung der Biologika (bDMARDs) wie TNF-, IL-17- und IL-23-Inhibitoren hat sich die Behandlung von Patienten mit axialer Spondyloarthritis (axSpA) und Psoriasis Arthritis (PsA) von Grund auf verändert. In Deutschland werden zwischen 30% und 50% der axSpA- und[zum vollständigen Text gelangen Sie über die oben angegebene URL], Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results